3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Cholangiocarcinoma
10
Acrocephalosyndactylia
6
Carcinoma, Transitional Cell
5
Neoplasm Metastasis
4
Breast Neoplasms
4
Gastrointestinal Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Stomach Neoplasms
2
Solid Tumor
2
Recurrence
2
Pancreatic Neoplasms
2
Neoplasms
2
Myeloproliferative Disorders
2
Lung Neoplasms
2
Endometrial Neoplasms
2
Colorectal Neoplasms
2
Carcinoma
2
Urinary Bladder Neoplasms
1
Solid Tumor, Miscellaneous
1
Sarcoma
1
Oligodendroglioma
1
Non-Muscle Invasive Bladder Neoplasms
1
Neoplasms, Unknown Primary
1
Multiple Myeloma
1
Lymphoma, Mantle-Cell
1
Lymphoma, B-Cell, Marginal Zone
1
Lymphoma, B-Cell
1
Locally Advanced Unresectable Gastric Cancer
1
Liposarcoma
1
Leukemia, Myeloid, Acute
1
Interventions
Radiotherapy
119
Temozolomide
109
Carboplatin
52
Filgrastim
46
Vincristine
42
Etoposide
39
Cyclophosphamide
36
Chemotherapy, Adjuvant
36
Cisplatin
35
Carmustine
32
Irinotecan
27
Peripheral Blood Stem Cell Transplantation
25
Magnetic Resonance Spectroscopy
23
Lomustine
22
Thiotepa
21
Methotrexate
19
Granulocyte Colony-Stimulating Factor
18
Procarbazine
16
Bevacizumab
16
Surgical Procedures, Operative
15
O(6)-benzylguanine
14
etoposide phosphate
13
Topotecan
12
Paclitaxel
12
Ifosfamide
12
Drug Therapy
12
Thalidomide
11
Radiation
11
sargramostim
10
Erlotinib Hydrochloride
9
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Central Nervous System Neoplasms
×
pemigatinib
×
Clear all
NCT05267106
2025-12-30
FIGHT-209
Incyte Corporation
Phase 2
Terminated
83 enrolled
18 charts